The company announces that it has completed patient enrollment in its multi-centre, Phase II, randomized, double-blind, placebo-controlled study to explore the efficacy and safety of Sevuparin infusion for the management of Acute Vaso-Occlusive Crisis (VOC) in patients with sickle cell disease.
This large, expanded, global Phase II study recruited over 140 patients at clinical sites across Europe and the Middle East. The study compared intravenously administered sevuparin with placebo in patients admitted to the hospital with an acute VOC associated with sickle cell disease. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient’s VOC.
The study was conducted in conjunction with Modus Therapeutics’ co-development partner Ergomed.
Sevuparin is a polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects. Sevuparin has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD.
“Painful crisis is a debilitating effect of SCD and we are committed to providing patients with an effective option to resolve these vaso-occlusive events in order to reduce their pain. We look forward to presenting our results later this year,” commented John Öhd, CMO of Modus Therapeutics.
Photo of John Öhd: Medivir